{"title":"老年营养风险指数评价胃癌根治术后预后的临床意义。","authors":"Mie Tanabe, Toru Aoyama, Itaru Hashimoto, Yuta Nakayama, Junya Morita, Kyohei Kanematsu, Shinsuke Nagasawa, Yukio Maezawa, Takanobu Yamada, Takashi Ogata, Aya Saito, Takashi Oshima","doi":"10.21873/invivo.14023","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The clinical evaluation of the GNRI in nutritional status management has been reported in several malignancies. This study aimed to investigate the relationship between the GNRI and clinical outcomes in postoperative patients who underwent radical gastrectomy.</p><p><strong>Patients and methods: </strong>Clinical data of 940 gastric cancer patients who underwent radical gastrectomy at Kanagawa Cancer Center from 2013 to 2020 were retrospectively collected and divided into a high-GNRI group (≥98) and a low-GNRI group (<98) according to the GNRI. The association between the GNRI and overall survival (OS) and recurrence-free survival (RFS) was investigated.</p><p><strong>Results: </strong>The respective 3- and 5-year OS rates were 92.0% and 86.3% in the high-GNRI group and 82.4% and 73.2% in the low-GNRI group (<i>p</i><0.001). A multivariate analysis showed that the GNRI was an independent predictor of the OS and RFS.</p><p><strong>Conclusion: </strong>GNRI is an objective, noninvasive, and easily accessible prognostic biomarker for gastric cancer patients. Patient stratification using the GNRI and preoperative nutritional interventions may improve prognosis.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2277-2285"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223658/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Significance of the Geriatric Nutritional Risk Index in the Evaluation of Outcomes of Patients After Radical Gastrectomy.\",\"authors\":\"Mie Tanabe, Toru Aoyama, Itaru Hashimoto, Yuta Nakayama, Junya Morita, Kyohei Kanematsu, Shinsuke Nagasawa, Yukio Maezawa, Takanobu Yamada, Takashi Ogata, Aya Saito, Takashi Oshima\",\"doi\":\"10.21873/invivo.14023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>The clinical evaluation of the GNRI in nutritional status management has been reported in several malignancies. This study aimed to investigate the relationship between the GNRI and clinical outcomes in postoperative patients who underwent radical gastrectomy.</p><p><strong>Patients and methods: </strong>Clinical data of 940 gastric cancer patients who underwent radical gastrectomy at Kanagawa Cancer Center from 2013 to 2020 were retrospectively collected and divided into a high-GNRI group (≥98) and a low-GNRI group (<98) according to the GNRI. The association between the GNRI and overall survival (OS) and recurrence-free survival (RFS) was investigated.</p><p><strong>Results: </strong>The respective 3- and 5-year OS rates were 92.0% and 86.3% in the high-GNRI group and 82.4% and 73.2% in the low-GNRI group (<i>p</i><0.001). A multivariate analysis showed that the GNRI was an independent predictor of the OS and RFS.</p><p><strong>Conclusion: </strong>GNRI is an objective, noninvasive, and easily accessible prognostic biomarker for gastric cancer patients. Patient stratification using the GNRI and preoperative nutritional interventions may improve prognosis.</p>\",\"PeriodicalId\":13364,\"journal\":{\"name\":\"In vivo\",\"volume\":\"39 4\",\"pages\":\"2277-2285\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223658/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"In vivo\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/invivo.14023\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14023","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Clinical Significance of the Geriatric Nutritional Risk Index in the Evaluation of Outcomes of Patients After Radical Gastrectomy.
Background/aim: The clinical evaluation of the GNRI in nutritional status management has been reported in several malignancies. This study aimed to investigate the relationship between the GNRI and clinical outcomes in postoperative patients who underwent radical gastrectomy.
Patients and methods: Clinical data of 940 gastric cancer patients who underwent radical gastrectomy at Kanagawa Cancer Center from 2013 to 2020 were retrospectively collected and divided into a high-GNRI group (≥98) and a low-GNRI group (<98) according to the GNRI. The association between the GNRI and overall survival (OS) and recurrence-free survival (RFS) was investigated.
Results: The respective 3- and 5-year OS rates were 92.0% and 86.3% in the high-GNRI group and 82.4% and 73.2% in the low-GNRI group (p<0.001). A multivariate analysis showed that the GNRI was an independent predictor of the OS and RFS.
Conclusion: GNRI is an objective, noninvasive, and easily accessible prognostic biomarker for gastric cancer patients. Patient stratification using the GNRI and preoperative nutritional interventions may improve prognosis.
期刊介绍:
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.